secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K/A
Filed at:   2023-08-16T23:59:59+00:00
Accession:  0001297184-23-000070
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar files BAQSIMI financials: 2022 revenue $139.3M, revenue less direct expenses $59.8M
--------------------------------------------------------------------------------

- BAQSIMI 2022 revenue $139.3M (up 23% YoY from $113.2M); revenue less direct expenses $59.8M vs -$2.3M in 2021.
- Q1 2023 revenue $31.4M, up 7.5% YoY from $29.2M; revenue less direct expenses $13.0M vs $9.2M.
- Acquisition terms: $500M cash at closing, $125M at one-year anniversary, plus up to $450M in sales milestones.
- Net intangible assets of BAQSIMI were $100.3M as of Dec 31, 2022; total assets acquired $187.6M.
- Audited abbreviated financial statements cover FY 2021-2022; unaudited for Q1 2023 and 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000070/0001297184-23-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000070/amph-20230630x8ka.htm
  HTML page:      https://secwatch.observer/filing/0001297184-23-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer